Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.
Dopamine is a chemical responsible for voluntary movement and the perception of rewards in the brain.
New findings could help scientists develop treatments for the condition known as ITP.
Brain scans of people who are in love look similar to scans of drug addicts.
OMRF received $1.8 million to look into the critical role of a particular protein.